Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04491227|
Recruitment Status : Enrolling by invitation
First Posted : July 29, 2020
Last Update Posted : July 29, 2020
The coronavirus (COVID-19) pandemic has created a significant strain on health care resources across the world for managing critically ill patients. Emerging reports from China, South Korea and Italy have reported varying incidence of acute kidney (AKI) ranging from 5-15% with a mortality of 60-80% however there is no systematic assessment of the risk factors, recognition, course and outcomes in patients with and without kidney disease whose course is complicated by AKI1-4. Patients with underlying CKD, immunosuppressed patients with renal transplants and ESKD patients are at high risk for COVID-19 infection and there is limited information on the effect of COVID-19 on the course and outcomes of these patients. The requirement for renal support including IHD, CRRT and sorbent based therapies has been variable and has contributed to the intense pressure on the nephrology and critical care providers for delivering these therapies. As the COVID-19 pandemic expands in the USA and abroad, there is an intense need to understand the epidemiology of the disease and the resources needed for renal support to inform clinical management and public health interventions.
In this study, the investigators aim to investigate health care facilities across the world (hospital wards, ICU, outpatient clinics, nursing homes, healthcare centers) to draw a global picture of incidence, risk factors, resources available for treatment and prognosis of acute and chronic kidney disease in patient with COVID 19 confirmed infection. The aim is to identify trends in patients with acute and chronic kidney disease, determine its incidence, treatment and outcomes in different settings across the world. This information will be used to develop and implement educational tools and resources to prevent deaths from AKI and progression of CKD in this and following pandemics.
|Condition or disease|
|Covid19 AKI CKD ESRD Transplant;Failure,Kidney|
Acute and Chronic kidney diseases are important causes of mortality and morbidity worldwide. The associated socioeconomic burden of kidney disease and AKI, as in some cases recovery is incomplete and chronic kidney disease (CKD) can arise, is a growing problem around the world. During the COVID 19 pandemic the incidence of AKI has been reported to be as low as 0.5% to as high as 23%. AKI was reported to develop at a median of 15 days in one study, and another study reported that most AKI developed within 7 days of admission. The data on acute kidney injury (AKI) in patients with COVID-19 is mostly from patients who are hospitalized, and in some studies limited to critically ill patients in the ICU. In ICU patients the requirement for renal support and mortality is reported to be high, however is a lack of epidemiological studies specifically designed to determine the impact of COVID 19 on kidney outcomes.
The mortality rate of patients with kidney dysfunction varies widely and is inversely related to country income and percentage of gross domestic product spent on total health expenditure. Several initiatives will be very insightful and identified important gaps in knowledge, more effort is required to understand this problem affecting all regions of the globe. In order to eventually implement resources and tools to help prevent, diagnose and treat patients with COVID 19 infection and kidney dysfunction, the investigators need to understand its incidence, risk factors, available resources and barriers to diagnosis and treatment.
This project will collect data on kidney function progression in patients infected with COVID 19 across the world. The study will open to individual physicians across the world who agreed to participate by providing de-identified clinical and lab data of patients with confirmed COVID 19 infection with acute and chronic kidney dysfunction.
1. Establish incidence and outcomes of acute kidney injury (AKI) in different settings worldwide during the COVID 19 pandemic.
- Compare risk factors, etiologies, diagnosis, management and outcomes of acute and chronic kidney dysfunction in COVID 19 patients in different countries
- Determine resources available for recognition, non-dialytic and dialytic management and follow up of patients with acute and chronic kidney dysfunction and COVID 19 infection in different settings and countries.
- Determine long term outcomes, 6 months and 1 year, of patients with acute and chronic kidney dysfunction and COVID 19 infection in different settings.
- Evaluate barriers preventing access to the standard treatments of acute and chronic kidney dysfunction and COVID 19 infection across different countries.
- Determine the impact of COVID 19 infection on the progression of acute and chronic kidney disease in patient with native and transplanted kidney.
- Evaluate the treatment strategies of patient with ESKD on hospitalized patients with COVID 19.
|Study Type :||Observational|
|Estimated Enrollment :||2000 participants|
|Official Title:||Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection|
|Actual Study Start Date :||May 5, 2020|
|Estimated Primary Completion Date :||April 30, 2022|
|Estimated Study Completion Date :||March 31, 2023|
Kidney disease in COVID-19
Chronic Kidney Disease (CKD): Known diagnosis of chronic kidney disease; prior evidence of markers of kidney damage for 3 months (microalbuminuria, proteinuria >300mg/24 hrs or abnormalities in imaging tests) or the presence of glomerular filtration rate (GFR) <60 mL/min/1.73 m2 for 3 months calculated with CKD-EPI equation, with or without other signs of kidney damage as described above.
ESKD: Patients that are dialysis dependent.
Suspected AKI: Oliguria (<200 mL/6 hours) and any AKI-related clinical signs or symptoms (see table 1) or urinalysis/dipstick abnormality. All suspected AKI cases must be confirmed prior to enrollment.
Confirmed AKI: Meeting of at least one of the modified KDIGO Criteria
Functioning Kidney transplant:
- AKI incidence [ Time Frame: from hospital admission through hospital discharge upto 24 weeks ]
Meeting of at least one of the modified KDIGO Criteria
- Increase or decrease in serum creatinine >0.3 mg/dl from reference in 48 hours
- Increase or decrease in serum creatinine > 50% from reference in 7 days
- Urine output < 400 ml/day
- Dialysis requirement [ Time Frame: through study completion upto 1 year from enrollment ]initiation of intermittent hemodialysis, continuous hemodialysis or peritoneal dialysis during the hospital stay
- hospital mortality [ Time Frame: through study completion within 1 year ]Deaths during primary hospitalization
- Renal functional recovery [ Time Frame: Assessed at at 3, 6 and 12 months from enrollment at hospital admission ]C-Complete: SCr < 0.3 mg/dL from reference P-Partial: Requires no dialysis but not complete recovery N-No recovery: Dialysis dependent C-Complete: SCr < 0.3 mg/dL from reference P-Partial: Requires no dialysis but not complete recovery N-No recovery: Dialysis dependent Percentage of patinets with renal functioanl recovery based on serum creatinien levels classfied as C-Complete: SCr < 0.3 mg/dL from reference P-Partial: Requires no dialysis but not complete recovery N-No recovery: Dialysis dependent
- Functional status [ Time Frame: questionnaires to be completed at 3, 6 and 12 months from enrollment at hospital admission ]EQL5D scale and SH8 scales completed at 3, 6 and 12 months post enrollment
- Resource utilization [ Time Frame: Within 1 year of enrollment for primary hospitalization ]Number of days patient is in the hospital and ICU and is managed with ventilators, dialysis or other extracorporeal organ support e.g. ECMO during the hospital stay
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04491227
|United States, Alabama|
|University of Alabama, Birmingham|
|Birmingham, Alabama, United States, 35294|
|United States, California|
|University of California, San Diego|
|San Diego, California, United States, 92103|
|United States, Colorado|
|University of Colorado|
|Aurora, Colorado, United States, 80045|
|United States, New York|
|St. Peter's Hospital|
|Albany, New York, United States, 12208|
|Jacobi Medical Center|
|New York, New York, United States, 10461|
|Hospital Obrero #2|
|Hopital Sacre Coeur & Universite de Montreal|
|Montreal, Quebec, Canada|
|Universidad de Los Andes|
|Postgraduate Institute of Research, Chandigarh|
|Royal Free Hospital|
|London, United Kingdom, NW3 2QG|
|Guy's & St Thomas's Hospital|
|London, United Kingdom, SE1 7EH|
|University of Nottingham|
|Nottingham, United Kingdom, NG7 2RD|
|Principal Investigator:||Ravindra L Mehta||University of California, San Diego|